On November 21, 2017 Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, reported Walter Klemp, Chairman and Chief Executive Officer and Jonathan Foster, Chief Financial Officer will present at the 10th Annual LD Micro Main Event on Tuesday, December 5, 2017 at 11:30 a.m. PT (2:30 p.m. ET) in Track 5 (Press release, Moleculin, NOV 21, 2017, View Source [SID1234522198]). The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Management will be available for one-on-one meetings on Tuesday, December 5, 2017. Investors interested in arranging a meeting with management should contact their LD Micro representative or Lytham Partners at (602) 889-9700 or [email protected].